The PRAMI trial, published in the New England Journal of Medicine, investigated in a multicentric randomised fashion whether “on the spot full revascularisation” provides outcome benefits in patients with multivessel disease presenting with a ST-elevation myocardial infarction (STEMI), as compared to a “culprit alone strategy”1. The study enrolled 465 patients with acute STEMI, who underwent primary PCI of the culprit lesion and were randomly assigned 1:1 either to “preventive PCI” of all non-culprit lesions with more than 50% diameter stenosis during the same procedure (234 patients) or to “no preventive PCI” (231 patients).
The study was terminated early on the advice of the data ...
NEW ISSUE
Infective Endocarditis & TAVI; Cerebral Protection Devices; IVUS Assessment in ViV-TAVI, Mini Focus on Antithrombotic Therapy …
February 19, 2021